The value of progression-free survival to patients with advanced-stage cancer
- 18 October 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 9 (1), 41-47
- https://doi.org/10.1038/nrclinonc.2011.156
Abstract
Progression-free survival (PFS) is frequently used as a primary end point in oncology clinical trials. Employing PFS instead of overall survival as the primary outcome has the advantage that trial completion can be quicker with fewer patients required, and it is cheaper. PFS is sensitive to cytostatic as well as cytotoxic mechanisms of therapeutic intervention and directly measures the effect of the investigational treatment. Despite these practical advantages, it is unclear whether or not extending PFS provides discernable clinical benefit. New treatments that increase PFS may not be of sufficient value to patients with advanced-stage cancer unless accompanied by tangible quantity or quality of life advantages. Any symptom relief that patients gain from treatment resulting in tumor shrinkage or stabilization must be balanced against the toxic effects that drug therapy itself creates. Consequently, improved assessment of new treatments using patient-reported outcomes alongside PFS is crucial to enable communication between clinicians and patients and optimal decision-making about therapeutic options.Keywords
This publication has 52 references indexed in Scilit:
- Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 MinutesJournal of Clinical Oncology, 2011
- The ethical use of mandatory research biopsiesNature Reviews Clinical Oncology, 2011
- Health-related quality of life and cancer clinical trialsTherapeutic Advances in Medical Oncology, 2011
- Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumabInternational Journal of Colorectal Disease, 2010
- Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?Annals Of Oncology, 2010
- End-of-Life Discussions, Goal Attainment, and Distress at the End of Life: Predictors and Outcomes of Receipt of Care Consistent With PreferencesJournal of Clinical Oncology, 2010
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion QuestionJNCI Journal of the National Cancer Institute, 2009
- Cancer patient preferences for quality and length of lifeCancer, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumabBritish Journal of Cancer, 2007